<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the last decade, significant advances have been made in the treatment of patients with <z:hpo ids='HP_0002863'>Myelodysplastic Syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Although best supportive care continues to have an important role in the management of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, to date the therapeutic approach is diversified according to the IPSS risk group, karyotype, patient's age, comorbidities, and compliance </plain></SENT>
<SENT sid="2" pm="."><plain>Hematopoietic growth factors play a major role in lower risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, and include high dose erithropoiesis stimulating agents and thrombopoietic receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Standard supportive care should also include iron chelating therapy to reduce organ damage related to <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in transfusion-dependent patients </plain></SENT>
<SENT sid="4" pm="."><plain>Biologic therapies have been introduced in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, as lenalidomide, which has been shown to induce transfusion independence in most lower risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with del5q </plain></SENT>
<SENT sid="5" pm="."><plain>Hypomethylating agents have shown efficacy in INT-2/high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, reducing the risk of leukemic transformation and increasing survival </plain></SENT>
<SENT sid="6" pm="."><plain>Other agents under development for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> include <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitors, farnesyltransferase inhibitors, clofarabine and ezatiostat </plain></SENT>
</text></document>